Study of special stem cells for severe skin peeling (SJS-TEN)
Part of Immune system & allergy, Mouth & dental, Skin clinical trials.
This early-phase trial tests stem-cell treatment to help people with severe skin reactions called SJS-TEN. It may reduce ongoing skin damage and help recovery when treatment is started soon after symptoms begin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old
- You’re in the hospital within 10 days of your first SJS-TEN symptoms
- Your doctors have confirmed SJS-TEN, and you’re admitted to dermatology or intensive care
- You have at least 10% skin area peeling or separating within the first 10 days
- You can give written consent (or your support person can help, if allowed by local rules)
- You’re covered by your country’s social security health system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
This trial tests if a drug called daratumumab can help people with a severe skin reaction (SJS/TEN) caused by a medication. It aims to stop the reaction from getting worse.
This trial tests a cell-based treatment (mesenchymal stromal cells) to help heal painful finger/toe ulcers in people with systemic sclerosis. It is for ulcers that did not improve after a specific IV medicine called prostacyclins.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
This Phase 1 study tests whether injected stem cells can help wounds heal faster or better. It focuses on people with specific wound types and sizes, and checks safety and wound healing over weekly visits.
Hear when a new Toxic Epidermal Necrolysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.